Hair loss edition · Most recent male pattern baldness conclusions
Last updatedMonday, November 2, 20266:43 AM ET · Updated weekly
Today's headlineVeradermics reported on October 19 that its extended-release oral minoxidil pill (VDPHL01) beat placebo in a Phase 3 trial of 536 men (company-reported); it is not approved. Clascoterone 5% plans a U.S. filing in early 2027. Finasteride and minoxidil remain the only FDA-approved medicines, and neither is a cure.
Male pattern baldness has no cure. Two approved medicines can slow it or partly reverse it while you keep using them.
Cure Checker's conclusion · Oct 2026
Most recent cure information
There is no cure for male pattern baldness (androgenetic alopecia). It is a common, inherited kind of hair loss: by age 50, more than half of white men show visible signs, according to the American Academy of Dermatology. It is not dangerous to health, but it can matter a lot to the people who have it. In the U.S., two medicines are approved for it: finasteride 1 mg tablets (prescription, approved December 19, 1997) and minoxidil applied to the scalp (over the counter). Neither is a cure. They slow loss or regrow some hair only for as long as they are used. Our view: the newest candidates, such as a hormone-blocking scalp solution called clascoterone, may add options, but none has been approved for hair loss yet.
A new scalp treatment is close to filing.Cosmo Pharmaceuticals says two Phase 3 trials of clascoterone 5% solution (1,465 men) beat a dummy solution, and 12-month data released April 15, 2026 showed continued growth with safety similar to the dummy. It plans a U.S. filing in early 2027. These are company-reported results.
Finasteride warnings got stronger.The FDA label lists depression, suicidal thoughts, and sexual problems that continued after stopping. In 2025 the EU confirmed suicidal thoughts as a side effect and added a patient card, and on May 11, 2026 the UK's MHRA strengthened its warnings again.
Oral minoxidil is being tested as a hair pill.Minoxidil tablets are FDA-labeled only for hard-to-treat high blood pressure. Veradermics reported on April 27, 2026 that an extended-release version beat placebo in a Phase 2/3 trial of over 500 men (company release). A second pivotal trial is expected to report later in 2026.
Popular add-ons have weaker proof.Laser devices are FDA-cleared, and reviews find modest gains. PRP injections and microneedling show promise, but studies are small and vary widely. Saw palmetto, rosemary oil and biotin lack good evidence.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Decisions about treatment belong with a doctor, ideally a dermatologist.
A possible missing link
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your dermatologist.
What looks like it is working
Blocking the hormone slows the damage. Of 126 Korean men who took finasteride for at least 5 years, 85.7% improved in a look-back study, though some areas thinned again later (J Dermatol, 2019).
The stem cells are still there. Bald scalp kept its hair follicle stem cells but lacked the "progenitor" cells they normally turn into to grow a new hair (J Clin Invest, 2011).
Wake-up signals work in the lab. In normal mice, raising lactate in follicle stem cells woke them and started a new hair cycle (Nat Cell Biol, 2017). A signal called WNT5A is switched off in stem cells from balding scalp; turning it on slowed hair loss in mice (Adv Sci, 2026). A gel meant to reactivate stem cells is in a larger trial (NCT07819435); its early results are company-reported only.
Where the links are missing
Removing one brake was not enough. Prostaglandin D2 is raised in bald scalp and blocks hair growth (Sci Transl Med, 2012), but a pill aimed at this pathway did not regrow hair in 169 men (Clin Cosmet Investig Dermatol, 2021). Our inference: stem cells may need both the hormone signal removed and a direct push.
A point of no return. Biopsies show inflammation around follicles early and scarring later, sometimes destroying them (J Cosmet Dermatol, 2009). Our inference: there is no simple test to tell which bald patches still have follicles that could recover.
Never tried together. The stem-cell gel trial excludes other hair loss treatments (ClinicalTrials.gov). Our inference: we found no trial pairing a stem-cell "wake-up" drug with a hormone blocker, though we may have missed one.
Our hypothesis
Could waking the stem cells that bald scalp still keeps, while the hormone signal is blocked at the same time, grow back full-size hairs that stay, instead of today's partial gains that fade when treatment stops? It could work only where scarring has not destroyed follicles; a test to find those areas does not yet exist.
What would prove it wrong: if follicles woken in bald scalp shrink again within a year or two even with the hormone blocked, or if the pair regrows no more hair than either part alone.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Latest studies & what they concluded
Newest first. Updated each morning as results, trial launches and papers are published.
Laser-assisted growth-factor serum plus red light: small pilot trial
In a small randomized pilot study in Germany, hair density rose 25.6% with laser-assisted serum plus red light, 22.7% with laser-assisted serum alone, and 4.9% with laser and red light without serum. No serious side effects were reported. It is a pilot with few people, two authors report lecture fees from laser makers, and it is not a proven treatment.
Extended-release oral minoxidil (VDPHL01): Phase 3 Study 304
In 536 men, hair counts rose by 28.6 (once daily) and 36.4 (twice daily) hairs per cm² at 6 months, vs 6.6 on placebo. Improved hair coverage was reported by 55.7% and 68.7% vs 15.0% on placebo. The company reported no treatment-related serious side effects. Swelling in the legs or feet affected 2.8% and 4.5% vs 0.6%, and extra hair growth elsewhere 2.2% and 9.0% vs 0%. Company-reported topline results, not peer-reviewed, and the pill is not approved for hair loss.
Platelet-rich plasma vs growth factor concentrate: systematic review
A review of 10 studies found that both platelet-rich plasma (PRP) and growth factor concentrate (GFC) injections improved hair density, thickness and patient satisfaction in androgenetic alopecia. Some studies favored GFC, but the studies were small and varied, so the authors say no winner can be declared and larger trials are needed.
Pelage Pharmaceuticals started a Phase 2/3 trial of PP405 0.05% scalp gel against a dummy gel in adult men, aiming for about 600 people at sites in the U.S. and Canada. In an earlier 78-person Phase 2a study, the company reported that 31% on PP405 had more than a 20% rise in hair density at week 8, vs 0% on placebo (company release, not peer reviewed).
Finasteride vs dutasteride pills: small randomized trial
In 46 men in Iran treated for 24 weeks, both pills improved hair growth with no significant difference between them. Sexual side effects were the most common, and erectile problems were more frequent with finasteride. No serious side effects occurred. Small and single-blind.
A review of 23 studies ranked topical minoxidil 5% as the most effective option for men. Several off-label topicals (including melatonin, saw palmetto and topical finasteride) showed possible benefit but need better trials. The authors work for a research company.
Lasers and light devices: meta-analysis of 37 studies
Across 3,298 patients, low-level laser therapy added about 18.6 hairs per cm² compared with sham devices, and more when combined with minoxidil. Side effects were mild and short-lived.
UK strengthens finasteride and dutasteride warnings
The MHRA updated product information to say sexual problems may contribute to mood disorders, and added a precautionary mood warning to dutasteride. UK patient alert cards for finasteride, introduced in 2024, stay in place.
In over 500 men, hair counts in the target area rose by 30.3 (once daily) and 33.0 (twice daily) hairs per cm² at 6 months, vs 7.3 on placebo. The company reported no treatment-related serious side effects and no heart-related side effects of special interest. A second pivotal trial is due to report in the second half of 2026. Company-reported.
Men who stayed on clascoterone kept gaining hair compared with those switched to the dummy solution at month 6. Cosmo reported safety similar to the dummy with no significant whole-body hormonal side effects. It plans a U.S. application (NDA) in early 2027 and a European one. Company-reported, not yet peer reviewed.
In 666 men at 26 centers in China, hair counts rose by 15.33 hairs per cm² on the 1.0% solution and 14.46 on 0.5%, vs 4.68 on placebo, over 24 weeks. Kintor reported no drug-related serious side effects and plans to file for approval in China. An earlier Phase 3 of the 0.5% dose (2023) did not reach statistical significance. Company-reported.
Family history, smoking, insulin resistance and, in men, high blood pressure were linked to having pattern hair loss. Alcohol, poor sleep and overweight were linked to faster progression. These are associations, not proof of cause.
In 1,465 men across two trials, clascoterone beat the dummy solution on hair count in the target area. Side effects were similar to the dummy. A patient-rated goal was met in one study and trended positive in the other. No sexual side effects were reported, according to Healio. Company-reported topline data.
In 180 Chinese men, two of the four GT20029 dosing schedules beat their placebo groups on hair count at 12 weeks. Side effects were mostly mild. GT20029 is designed to break down the androgen receptor.
PRP injections vs topical minoxidil: meta-analysis
Nine randomized trials (451 people) found no clear difference in hair density or terminal hair count between platelet-rich plasma and minoxidil, though patients were more satisfied with PRP. Studies varied widely.
EU confirms suicidal thoughts as a finasteride side effect
After a review that began with its safety committee (PRAC recommendation May 8, 2025), the European Commission's decision confirmed suicidal ideation as a side effect of finasteride tablets, frequency unknown. A patient card goes in 1 mg packs. Regulators said benefits still outweigh risks for approved uses.
The FDA said there is no FDA-approved topical finasteride and reported 32 adverse-event reports from 2019 to 2024 for compounded versions, many saying effects persisted after stopping.
In 270 Chinese men, the spray increased hair count over placebo at 24 weeks and was generally well tolerated. The trial was funded by the drug's developer.
Two medicines are FDA-approved for male pattern hair loss. They work only while used. Hair transplant surgery moves hair rather than stopping the process.
Finasteride 1 mg (Propecia)
FDA approved
Approved Dec 19, 1997 · prescription tablet · men only
Lowers DHT, the hormone that shrinks hair follicles. The AAD says it slowed further loss in about 80% to 90% of men. The label lists sexual side effects, including some that continued after stopping, and depression and suicidal thoughts.
Minoxidil on the scalp
FDA approved
Approved Aug 17, 1988 · over the counter since 1996
A liquid or foam. The 5% liquid for men was approved in 1997 and the 5% foam in 2006. The AAD says results can take up to 6 to 12 months to show.
Dutasteride
Approved abroad
South Korea 2009 · Japan · U.S.: prostate only
A stronger DHT blocker. It is approved for male pattern hair loss in South Korea and Japan. In the U.S. it is approved only for an enlarged prostate, so hair use is off-label.
Oral minoxidil
Off-label
Tablets labeled only for severe high blood pressure
In a 2024 trial of 68 men, 5 mg pills were not better than 5% scalp minoxidil overall, and 49% grew unwanted body hair. A purpose-built extended-release version is in Phase 3.
Clascoterone 5% solution
Phase 3 done
Cosmo Pharmaceuticals · U.S. filing planned early 2027
A scalp solution that blocks androgen receptors in the skin. Two Phase 3 trials met their main goal (company-reported). Not approved for hair loss anywhere.
Hair transplant surgery
Established
Moves hair follicles from the back of the scalp
In a 2025 survey of hair restoration surgeons, 85% of men's cases used the FUE method. The AAD calls results permanent and natural-looking, but surgery does not stop further loss.
Standard treatment today
Treatment
For
What it does
Finasteride 1 mg tablet
Men (prescription)
Lowers DHT to slow loss and regrow some hair. Benefits fade if stopped.
Minoxidil 5% liquid or foam
Men (over the counter)
Stimulates growth and slows loss. Benefits fade if stopped.
Low-level laser devices
FDA-cleared, not approved
Modest gains in density in reviews of trials. Needs many sessions.
Platelet-rich plasma (PRP)
In-office injections
May lessen hair loss. Studies vary in method and quality.
Hair transplant
Stable, suitable donor hair
Moves existing follicles to thinning areas.
Natural remedies & supplements
Hair loss products are heavily marketed. None of these is FDA-approved to regrow hair, and most of the studies are small. We rate each by the strength of evidence.
Strong evidenceLimited / mixed evidenceWeak or no evidence, or possible harm
Some evidence, still limited
Microneedling with minoxidil
A 2025 review of 12 trials (631 people) found more hair with microneedling plus minoxidil than minoxidil alone, but results varied a lot and side effects were more frequent. The British Association of Dermatologists says little research supports it.
Ketoconazole shampoo
A 2020 review found 5 small human studies (318 people) and called it promising as an add-on, but said randomized trials are needed.
Pumpkin seed oil capsules
One 2014 trial in 76 men found more hair than placebo after 24 weeks. One trial is not enough to be sure.
Weak or no evidence
Saw palmetto
The NIH's NCCIH says a few small studies exist and the evidence is too limited to draw conclusions.
Rosemary oil
One 2015 trial (100 people) found it similar to 2% minoxidil, the weaker strength, with no placebo group. Not enough to recommend it.
Biotin
A 2017 review found benefit only in people with an underlying cause of poor hair growth, not in healthy people. High doses can throw off lab tests.
Caffeine shampoos and liquids
One open-label 2017 trial compared a caffeine liquid with 5% minoxidil on a lab measure of growing hairs, not hair counts. Not enough to rely on.
Scalp massage
A 2016 study of 9 healthy men with no comparison group found slightly thicker hairs. It did not study men with pattern baldness.
Be careful: biotin in many hair supplements can cause falsely high or low lab results, including heart tests, so tell your doctor if you take it. The FDA says there is no FDA-approved topical finasteride and has warned about compounded versions. Be wary of "cure" or "regrowth guaranteed" claims: for over-the-counter scalp products, the FDA has ruled that hair-growth claims are unsupported unless the product has gone through approval, as minoxidil has.
Where to get care and support
Places with verifiable expertise in hair loss, and communities of people living with it.
Where people find expert care
University of Minnesota Hair Disease Specialty ClinicMinneapolis, Minnesota, USA
An academic dermatology clinic for hair disorders, including male pattern baldness. The University of Minnesota was a site in the SCALP 1 Phase 3 trial of clascoterone.
Mayo Clinic's Department of Dermatology in Jacksonville was a site in the SCALP 1 Phase 3 trial of clascoterone. Mayo also describes hair-loss care at its campuses.
Charité Clinical Research Center for Hair and Skin ScienceBerlin, Germany
A university research center whose stated focus includes hereditary hair loss in men and women. It was a site in the SCALP 2 Phase 3 trial of clascoterone.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Support groups & communities
Hair loss can affect confidence and mood. Talking with others can help. Many hair-loss sites also sell products, so we note that where we saw it.
Alopecia UK
Charity
UK charity · groups and online community
Runs support groups, events and private online groups. Its focus is mainly alopecia areata, but the British Association of Dermatologists lists it for male pattern hair loss.
Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Hair-loss communities often include product promotion and strong opinions about medicines, so look for sources. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
How other countries treat male pattern baldness
Finasteride and minoxidil are available in many countries. Dutasteride is approved for hair loss in South Korea and Japan, and a finasteride scalp spray is authorized in Europe.
What's available
Treatment
U.S.
EU
UK
Canada
Japan
S. Korea
China
Australia
Switz.
Finasteride 1 mg tabletsPrescription
Approved 1997
Approved
Approved
Approved
—
—
—
—
Approved
Minoxidil on the scalpLiquid or foam
Approved 1988
—
Approved
Approved
—
—
—
—
Approved
DutasterideOral, for hair loss
Prostate only
—
—
—
Approved
Approved 2009
—
—
—
Finasteride scalp sprayTopical
Not approved
Some countries
—
—
—
—
Phase 3 done
—
—
Clascoterone 5% solutionNew, topical
Filing 2027
Filing planned
—
—
—
—
—
—
—
Pyrilutamide (KX-826)New, topical
—
—
—
—
—
—
Phase 3 done
—
—
Approved approved for male pattern hair lossPhase 3 in late trials or awaiting a filing— not verified for this report, or not approved for hair loss
What's being studied abroad
China
Phase 3
Kintor · pyrilutamide (KX-826) 1.0%
A 666-man Phase 3 trial met its main goal, according to the company, which plans to file for approval in China. Not approved anywhere yet.
Since 2020, finasteride has been authorized in some EU countries as a spray applied to the scalp. The EU found the evidence insufficient to link the spray to suicidal thoughts.
Dutasteride is approved for male pattern hair loss in South Korea (2009) and Japan. In Seoul, a Phase 3 trial is comparing a new drug, CKD-843, with dutasteride.
The FDA approves minoxidil solution (Rogaine) on August 17. It goes over the counter in 1996.
The FDA approves finasteride 1 mg (Propecia) on December 19.
The FDA clears the HairMax LaserComb, a home laser device, for men with pattern hair loss (January 18).
South Korea approves dutasteride for male pattern hair loss. Japan follows after a 2015 review.
The FDA updates the finasteride label on suicidal thoughts and sexual side effects (August 1).
The FDA warns about compounded topical finasteride (April). The EU confirms suicidal thoughts as a side effect (August). Clascoterone Phase 3 results (December).
Positive Phase 3 data for pyrilutamide in China (March), 12-month clascoterone data (April), and oral minoxidil trial results (April). The UK strengthens warnings (May).
What causes male pattern baldness
It comes from inherited genes plus the hormone DHT. In men with the genetic tendency, DHT gradually shrinks hair follicles on the top and front of the scalp, so the hairs they make get thinner and shorter.
Step 1 · The genes
An inherited tendency
More than halfof white men by 50
Many genes: a 2018 study of 205,327 men found 624 gene regions linked to it
Mother's side counts: a key gene, for the androgen receptor, sits on the X chromosome, which men get from their mother
Step 2 · The tipping point
Testosterone becomes DHT
An enzyme, type II 5-alpha reductase, is found in hair follicles and makes DHT
Finasteride and dutasteride block this enzyme
Step 3 · The change
Follicles shrink
Miniaturization: balding scalp has smaller follicles and more DHT than hairy scalp
Thinner hairs: thick hairs are slowly replaced by fine, short ones
Step 4 · The result
A typical pattern
Loss is most visible at the temples and the crown
Doctors often grade it on the Hamilton-Norwood scale
Genetics (2018): a study of 205,327 men found 624 gene regions linked to male pattern baldness and estimated it is strongly inherited. No single gene decides it.
DHT (FDA label): the enzyme that makes DHT is found in hair follicles. This is why blocking it with finasteride slows hair loss in many men.
Follicle miniaturization (FDA label): balding scalp has shrunken follicles and more DHT than scalp with hair. Treatments aim to stop or partly reverse this shrinking while they are used.
Find a clinical trial
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Where hair-loss trials are recruiting right now
Loading live data from ClinicalTrials.gov…
Drug trials with no U.S. site
Newest published clinical trials
PubMed · U.S. National Library of Medicine
Loading…
Newest Cochrane systematic reviews
Cochrane Database of Systematic Reviews, via PubMed
Loading…
Newest trials in the EU registry
EU Clinical Trials Information System
Newest UK & international registrations
ISRCTN registry
Loading…
FDA records for the medicines in this report
Medicine
Brand
FDA application
Original approval
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
Search every registry yourself
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
Sources
Everything this report is based on, grouped by section. Checked October 5, 2026.
Also cited in this block and listed above: ClinicalTrials.gov NCT07819435 (PP405 Phase 2/3 trial; eligibility excludes other hair loss treatments) and the Pelage Phase 2a press release (company source).
Not individually cited: that thick hairs are gradually replaced by finer, shorter ones (a standard description of miniaturization). The "EU: Approved" cell for finasteride 1 mg rests on the EMA referral covering 1 mg packs in EU countries, not on a single EU-wide authorization. Japan's approval of dutasteride is based on the PMDA review report dated September 4, 2015; the exact approval day was not verified. Unverified and shown as "—": finasteride and minoxidil status in Japan, South Korea, China and Australia (Australia's registry could not be opened), and minoxidil in the EU. The approval status of the finasteride spray in China and any filing for pyrilutamide in China are not confirmed. Clascoterone, pyrilutamide, VDPHL01 and PP405 results come from company releases, not peer-reviewed papers. We found no FDA or AAD page stating outright that PRP is unapproved for hair loss, so this page does not claim it. The Mayo Clinic page blocks automated checks; it was confirmed through search results. The r/tressless community was confirmed only through third-party statistics sites. Expert care centers: no official center-of-excellence designation for hair loss could be verified, so the four centers listed are included for a registered Phase 3 trial role, plus a published hair-disorder program where one exists. Seoul National University Hospital is listed for its trial role only.